Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (¹⁸F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients

References

• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492–507.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a ‘state of the science’ review. Neuro-Oncology 2014;16:896–913.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-treating fields plus maintenance Temozolomide vs Maintenance Temozolomide alone on survival in patients with glioblastoma: a Randomized Clinical Trial. JAMA 2017;318:2306.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Tzaridis T, Mack F, et al. ACTR-58. Phase III trial of CCNU/Temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients: the CeTeg/NOA-09 trial. Neuro-Oncology 2017;19:vi13–vi14.
   Google Scholar
• Palucka K, Banchereau J. Dendritic-Cell-Based therapeutic cancer vaccines. Immunity 2013;39:38–48.
   PubMed Web of Science ®Google Scholar
• Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R. Dendritic Cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol. 2015 May 20;6:243.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91:1656–62.,
   PubMed Web of Science ®Google Scholar
• Cho D-Y, Yang W-K, Lee H-C, et al. Adjuvant Immunotherapy with Whole-Cell Lysate Dendritic Cells Vaccine for Glioblastoma Multiforme: a Phase II Clinical Trial. World Neurosurg 2012;77:736–44.,
   PubMed Web of Science ®Google Scholar
• Cao J-X, Zhang X-Y, Liu J-L, et al. Clinical efficacy of tumor Antigen-Pulsed DC treatment for High-Grade glioma patients: evidence from a Meta-Analysis. PLoS One 2014;9:e107173.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for High-grade Gliomas: response assessment in Neuro-Oncology Working Group. JCO 2010;28:1963–72.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534–e542.
   PubMedGoogle Scholar
• Galldiks N, Stoffels G, Filss C, et al. The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 2015;17:1293–300.
   PubMed Web of Science ®Google Scholar
• Beez T, Boge K, Wager M, et al. Tolerance of awake surgery for glioma: a prospective European Low Grade Glioma Network multicenter study. Acta Neurochir 2013;155:1301–8.
   PubMed Web of Science ®Google Scholar
• Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003;26:374–83.
   PubMed Web of Science ®Google Scholar
• Rapp M, Ozcan Z, Steiger H-J, et al. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. JNS 2006;105:41–50.
   PubMed Web of Science ®Google Scholar
• Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isotopes 2002;57:853–6.
   PubMed Web of Science ®Google Scholar
• Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–87.
   PubMed Web of Science ®Google Scholar
• de Wit MCY, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535–7.
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, et al. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci Usa 2017;114:10220–5.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med 2016;375:2561–9.,
   PubMed Web of Science ®Google Scholar
• Migliorini D, Dietrich P-Y, Stupp R, et al. CAR T-Cell therapies in glioblastoma: a first look. Clin Cancer Res 2018;24:535–40.
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Rapp M, Sorg RV, et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 2006;59:988–1000.
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098–104.,
   PubMed Web of Science ®Google Scholar
• Polyzoidis S, Tuazon J, Brazil L, et al. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. Brit J Neurosurg 2015;29:197–205.
   PubMed Web of Science ®Google Scholar
• Chen R, Cohen AL, Colman H. Targeted therapeutics in patients with High-Grade gliomas: past, present, and future. Curr Treat Options in Oncol 2016;17:42.
   Web of Science ®Google Scholar
• Finocchiaro G, Pellegatta S. Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. Cancer Immunol Immun 2016;65:101–9.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Mitchell DA. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol 2017;39:225–39.
   PubMed Web of Science ®Google Scholar
• Buchroithner J, Erhart F, Pichler J, et al. Audencel immunotherapy based on dendritic cells has no effect on overall and Progression-Free survival in newly diagnosed glioblastoma: A phase II randomized trial. Cancers 2018;10:372.
   PubMed Web of Science ®Google Scholar
• Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009;29:1–42.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. JCO 2011;29:330–6.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Stoffels G, Filss CP, et al. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J. Nucl. Med 2012;53:1367–74.,
   PubMed Web of Science ®Google Scholar